Arecor Therapeutics takes existing pharma products and reformulates them for new uses or to make them more effective. This reduces the risk, compared with developing completely new drugs. Arecor has secured partnerships for some products, but the insulin products for diabetes are being developed to the phase II clinical trial stage and then a partner […]

The post New AIM admission: Arecor Therapeutics appeared first on UK Investor Magazine.

Novo Nordisk UK (CPH:NOVO-B) has announced it is building up a four-month stock-pile in the event of a no-deal Brexit. The Danish company is taking this action in order to ensure patients’ insulin supply remains unaffected in the event of a no-deal Brexit. The global pharmaceutical company founded in 1923 has its headquarters in Denmark. […]

The post Novo Nordisk UK announces no-deal Brexit contingency plan appeared first on UK Investor Magazine.